drugset
drugset / Trial / NCT00336700

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

NCT00336700 ↗

Phase 2 Terminated 25 enrolled Herbert J. Zeh, III MD, FACS Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12 months.

Timeline

Start
2006-06
Primary completion
2011-10
Completion
2011-11

Outcome

Outcome not reported

Stopped: “Study published November 2010 and no further work will be done”

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg Oral
Subject Gemcitabine Small molecule 1500 mg/m2 Intravenous

Indications

malignant pancreatic neoplasm